TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 12204509
Drug: Folic acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic acid 5 mg and cobalamin 400 microg daily
Study: 10476895
Drug: GBA group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: GBA group (polylactide bioabsorbable membrane, DFDBA plus antibiotics)
Study: 6299752
Drug: Mianserin (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (acute and chronic administration)
Study: 6299752
Drug: Mianserin (acute
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mianserin (acute administration)
Study: 30272851
Drug: Probiotic capsule
Normalized name: GNP Probiotic Capsule
DrugBank: Bifidobacterium longum (DB19248)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic capsule of Bifidobacterium longum and Lactobacillus acidophilus (2 × 10^7 CFU/day)
Study: 30272851
Drug: Prebiotic (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prebiotic (10 g/day inulin)
Study: 30272851
Drug: Co-administration of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Co-administration of probiotic and prebiotic
Study: 26386707
Drug: Metronomic chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metronomic chemotherapy (methotrexate and celecoxib)
Study: 8716209
Drug: Cisplatin chemotherapy
Normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cisplatin chemotherapy
Study: 23193218
Drug: Mindfulness‐Based Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mindfulness‐Based Cognitive Therapy (MBCT)
Study: 16303697
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements (1 mg/kg/d) from 4‐9 mo of age
Study: 16303697
Drug: Iron supplements
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron supplements from 6‐9 mo
Study: 9856716
Drug: Tenoxicam (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenoxicam (2 mg) with lidocaine, 2% epidurally and lidocaine, 1% for local skin infiltration
Study: 8669876
Drug: 5 ml
Normalized name: WATER,INHL 5 ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 ml of fibrin glue (Tissucol) applied to the wound cavity
Study: 692548
Drug: Low compliance
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low compliance with treatment
Study: 22506692
Drug: Topical 5%
Normalized name: urea topical 5% topical lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 5% tranexamic acid
Study: 20688744
Drug: Saffron 20
Normalized name: SAFFRON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saffron 20 mg/d
Study: 12949718
Drug: Rofecoxib 25
Normalized name: rofecoxib 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rofecoxib 25 mg daily for >14 days
Study: 10566707
Drug: Sumatriptan 6
Normalized name: sumatriptan 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sumatriptan 6 mg subcutaneous (s.c.)
Study: 8678099
Drug: Cefepime 1
Normalized name: cefepime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefepime 1 g every 12 hours
Study: 8678099
Drug: Ceftazidime 1
Normalized name: ceftazidime 1000 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftazidime 1 g every 8 hours
Study: 1985504
Drug: ORG 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9426 (up to 5 maintenance doses)
Study: 1985504
Drug: ORG 9426
Normalized name: ORG-34517
DrugBank: ORG-34517 (DB05423)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORG 9426 (doses used in the study)
Study: 6684719
Drug: Aztreonam (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aztreonam (1 g every 8 hours for 5 to 10 days)
Study: 6684719
Drug: Cefamandole (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefamandole (1 g every 8 hours for 5 to 10 days)
Study: 29858418
Drug: Sham acupuncture
Normalized name: BLACK BEAN ANTI HAIR LOSS SHAM POO SET KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sham acupuncture and real medicine (topiramate)
Study: 18548084
Drug: Oral patterned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral patterned entrainment intervention (synthetically patterned orocutaneous pulse trains through a pneumatically controlled silicone pacifier)
Study: 18548084
Drug: Oral patterned
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral patterned entrainment intervention
Study: 15935981
Drug: High-dose hGH
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose hGH (16 U/d) for nine days
Study: 12796368
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human LIF (rhLIF) at doses of 0.25‐16.0 micro g/kg/day or 4.0 micro g/kg three times daily for 7 days
Study: 12796368
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human LIF (rhLIF) at doses of 0.25‐8.0 micro g/kg/day once daily for 14 days or 4.0 micro g/kg three times daily for 7 days
Study: 12796368
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human LIF (rhLIF) at doses of >/=4.0 micro g/kg/day
Study: 12796368
Drug: recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: recombinant human LIF (rhLIF) at higher doses
Study: 8393398
Drug: Nedocromil sodium
Normalized name: Nedocromil Sodium
DrugBank: Nedocromil (DB00716)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nedocromil sodium (4 mg, four times daily)
Study: 8393398
Drug: Cromolyn sodium
Normalized name: Cromolyn Sodium
DrugBank: Cromoglicic acid (DB01003)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cromolyn sodium (2 mg, four times daily)
Study: 3575558
Drug: Lithium (mean
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lithium (mean plasma level: 0.65 mmol/l)
Study: 29175417
Drug: CC genotype
Normalized name: dengue virus live antigen, CYD serotype 1 / dengue virus live antigen, CYD serotype 2 / dengue virus live antigen, CYD serotype 3 / dengue virus live antigen, CYD serotype 4 Injection [Dengvaxia]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC genotype for the ESRRB (rs1676303) gene
Study: 23278618
Drug: 0.15% ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15% ivermectin lotion
Study: 23278618
Drug: 0.25% ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.25% ivermectin lotion
Study: 23113480
Drug: 0.5% ivermectin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5% ivermectin lotion
Study: 18452785
Drug: CCM ON
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCM ON therapy for 3 months
Study: 18452785
Drug: CCM OFF
Normalized name: Off! Explore
Approvals — FDA: no, EMA: no, PMDA: no
Description: CCM OFF therapy for 3 months
Study: 12939429
Drug: Oral modified
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral modified cobratoxin
Study: 10845438
Drug: Ambroxol treatment
Normalized name: ambroxol
DrugBank: Ambroxol (DB06742)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ambroxol treatment (30 mg kg(‐1) over the first 5 days)
Study: 8403133
Drug: Captopril 50
Normalized name: captopril 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril 50 mg orally
Study: 31023843
Drug: Gefapixant 100
Normalized name: Gefapixant
DrugBank: Gefapixant (DB15097)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Gefapixant 100 mg
Study: 24395447
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 20 mg daily for 2 years
Study: 24395447
Drug: Doxorubicin (A)
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxorubicin (A) 40 mg/m2 and Cyclophosphamide (C) 500 mg/m2 plus Tamoxifen (ACT)
Study: 2172393
Drug: Oka/Merck varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka/Merck varicella vaccine (lot C-K472) with 950 pfu and relative antigen content of 1.0
Study: 2172393
Drug: Oka/Merck varicella
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oka/Merck varicella vaccine with 1140 pfu/1.7 relative antigen or 1145 pfu/1.6 relative antigen
Study: 2172393
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (Oka/Merck varicella vaccine with 950 pfu/1.0 relative antigen content)
Study: 30932775
Drug: Lutein complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lutein complex supplementation (10 mg lutein, 500 mg ascorbic acid, 364 mg tocopherols, 2.5 mg carnosic acid, 2 mg zeaxanthin, 2 mg copper)
Study: 24418801
Drug: Active low-level
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Study: 24418801
Drug: Placebo low-level
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo low-level laser therapy (LLLT) applied at five acupuncture points on the affected knee during nine sessions.
Study: 22079773
Drug: 75 mg
Normalized name: talc 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75 mg XR‐NTX
Study: 22079773
Drug: 150 mg
Normalized name: pectin 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150 mg XR‐NTX
Study: 22079773
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg XR‐NTX
Study: 19330703
Drug: 3 hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 hourly feeds
Study: 19330703
Drug: 2 hourly
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 hourly feeds
Study: 7814759
Drug: Transmandibular implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transmandibular implant
Study: 15346755
Drug: Augmentation of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation of the mandible with an autologous bone graft followed by placement of 4 endosseous implants
Study: 15346755
Drug: Placement of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placement of 4 endosseous implants only
Study: 11224756
Drug: Iomeprol-containing liposomal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iomeprol-containing liposomal formulations
Study: 9586887
Drug: Treatments containing
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments containing interferon (IFN)
Study: 9586887
Drug: Treatments without
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatments without interferon (IFN)
Study: 2719175
Drug: Histamine chloride
Approvals — FDA: no, EMA: no, PMDA: no
Description: Histamine chloride control (10 mg/ml)
Study: 24746974
Drug: Lupin protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lupin protein (LP) 25 g/d
Study: 23054692
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg empagliflozin q.d. for 5 days
Study: 23054692
Drug: Coadministration of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coadministration of 50 mg empagliflozin q.d. and 100 mg sitagliptin q.d. over 5 days
Study: 23054692
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg sitagliptin q.d. for 5 days
Study: 15601268
Drug: Pethidine 15
Normalized name: Pethidine
DrugBank: Meperidine (DB00454)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pethidine 15 mg with a 10‐min lockout
Study: 10506687
Drug: Ocular spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular spray administration
Study: 10506687
Drug: Ocular drops
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ocular drops administration
Study: 7503039
Drug: Low level
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low level laser therapy (LLLT) with a 30 mW gallium-arsenide-aluminium (830 nm) diode laser probe for 15, 30, and 60 seconds.
Study: 7503039
Drug: Placebo treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo treatment for 30 seconds.
Study: 2020093
Drug: Midazolam 4
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam 4 mg i.m. (Group M)
Study: 2020093
Drug: Hydroxyzine 50
Normalized name: hydroxyzine hydrochloride 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxyzine 50 mg i.m. (Group H)
Study: 2020093
Drug: Midazolam 2
Normalized name: midazolam 2 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam 2 mg and pentazocine 6 mg for intraoperative sedation (both groups)
Study: 2020093
Drug: Midazolam and
Normalized name: Midazolam
DrugBank: Midazolam (DB00683)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Midazolam and pentazocine maintenance doses (both groups)
Study: 6121709
Drug: Somatostatin with
Normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Somatostatin with prior indomethacin administration
Study: 25791145
Drug: Duloxetine (30‐120
Approvals — FDA: no, EMA: no, PMDA: no
Description: Duloxetine (30‐120 mg daily)
Study: 23397566
Drug: Antibiotic-impregnated catheters
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Antibiotic-impregnated catheters (Bactiseal(®))
Study: 17159373
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO) - Group A: 2.2 bar for 60 min bottom time
Study: 17159373
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen treatment (HBO) - Group B: 2.5 bar for 60 min bottom time
Study: 15602194
Drug: RIX4414 live
Normalized name: HUMAN ROTAVIRUS A TYPE G1P(8) STRAIN RIX4414 LIVE ANTIGEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: RIX4414 live attenuated human rotavirus vaccine
Study: 11529281
Drug: omalizumab during
Normalized name: Omalizumab
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: omalizumab during the steroid-reduction phase
Study: 9753250
Drug: rebamipide 100
Normalized name: Rebamipide 100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: rebamipide 100 mg thrice daily for eight weeks
Study: 9753250
Drug: teprenone 50
Normalized name: teprenone
DrugBank: Teprenone (DB15955)
Approvals — FDA: no, EMA: no, PMDA: no
Description: teprenone 50 mg thrice daily for eight weeks
Study: 7877584
Drug: SST+MLD (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST+MLD (standard surgical treatment plus medicinal lymph node dissection)
Study: 7877584
Drug: SST only
Approvals — FDA: no, EMA: no, PMDA: no
Description: SST only (standard surgical treatment)
Study: 2899718
Drug: Intravenous recombinant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous recombinant human tissue‐type plasminogen activator (rt‐PA)
Study: 27864462
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy (IAT) for grade 3 collateral status
Study: 27864462
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy (IAT) for grade 2 collateral status
Study: 27864462
Drug: Intra-arterial therapy
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial therapy (IAT) for grade 1 collateral status
Study: 26334726
Drug: Fixed-dose intravenous
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose intravenous combination of 3 mg/mL ibuprofen and 10 mg/mL paracetamol
Study: 26334726
Drug: Oral formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral formulation of the same doses of ibuprofen and paracetamol
Study: 16611155
Drug: Pharmacological agents
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological agents to prevent aneurysm expansion and rupture
Study: 9812477
Drug: Salmonella typhi
Normalized name: Salmonella Typhi Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salmonella typhi Vi capsular polysaccharide vaccine (Vi)
Study: 9812477
Drug: Diluted solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diluted solution (DS) of Vi (placebo)
Study: 3034469
Drug: Cilazapril 4
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 4 mg
Study: 7898090
Drug: Cilazapril (1.25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril (1.25, 3.75, 10, and 30 mg)
Study: 31241192
Drug: Nurse-led asthma
Normalized name: epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nurse-led asthma management and routine treatment measures (including inhaled corticosteroids)
Study: 24733191
Drug: MTX 12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX 12.5 mg once a week
Study: 24733191
Drug: TwHF 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: TwHF 20 mg three times a day
Study: 24733191
Drug: MTX+TwHF combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: MTX+TwHF combination
Study: 23141837
Drug: Budesonide 400μg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Budesonide 400μg/day plus immunotherapy
Study: 21705894
Drug: Daily evaluation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily evaluation and spontaneous breathing test with 10 cm H2O pressure support and 5 cm H2O positive end-expiratory pressure for 2 hours
Study: 6359996
Drug: Antibody detection
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibody detection by enzyme‐linked immunosorbent assay
Study: 30046691
Drug: Idarucizumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (1, 2, 4, or 8 g)
Study: 30046691
Drug: Idarucizumab (1,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Idarucizumab (1, 2, 4, or 5 g) with dabigatran (220 mg bid)
Study: 22813840
Drug: Sertraline plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sertraline plus aripiprazole
Study: 19318984
Drug: Atorvastatin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (in amlodipine-based therapy)
Study: 19318984
Drug: Atorvastatin (in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (in atenolol-based therapy)
Study: 17728418
Drug: Intensive psychosocial
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive psychosocial intervention (30 sessions over 9 months of interpersonal and social rhythm therapy, cognitive behavior therapy [CBT], or family‐focused therapy)
Study: 17728418
Drug: Collaborative care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Collaborative care (a 3‐session psychoeducational treatment)
Study: 15637976
Drug: Manual toothbrushing
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrushing coupled with daily flossing (positive control)
Study: 11431729
Drug: L-NMMA (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NMMA (3 mg/kg bolus plus 0.05 mg/kg.min for 120 minutes)
Study: 9736100
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (home care treatment)
Study: 8303937
Drug: DTP whole‐cell
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTP whole‐cell pertussis vaccine
Study: 2659874
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg finoptin
Study: 2659874
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg fosfobion
Study: 28482839
Drug: Alkanna tinctoria
Normalized name: ALKANNA TINCTORIA ROOT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alkanna tinctoria extract ointment (20%)
Study: 21770995
Drug: Mechanical debridement
Normalized name: PIPERONYL BUTOXIDE TECHNICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mechanical debridement (MDA) using carbon curets and antiseptic therapy with chlorhexidine digluconate
Study: 19309347
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolevulinate (MAL) photodynamic therapy (PDT)
Study: 1561524
Drug: Omeprazole (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omeprazole (40 mg every morning for 10 days)
Study: 4015380
Drug: Combined radiation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined radiation and fluorouracil as adjuvant therapy
Study: 29121431
Drug: 0.05% clobetasol
Normalized name: CLOBETASOL PROPIONATE 0.5 mg in 1 g TOPICAL CREAM [Clobetasol Propionate Cream, 0.05% Clobetasol Propionate Cream, 0.05%]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% clobetasol propionate (CP) in aqueous solution (AS)
Study: 29121431
Drug: 0.05% triamcinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.05% triamcinolone acetonide (TA) in aqueous solution (AS)
Study: 29121431
Drug: Maintenance treatment
Normalized name: Dental Resources Perio Maintenance Rinse
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maintenance treatment for >6 months
Study: 27615399
Drug: Annual trans-vaginal
Normalized name: annual bluegrass pollen extract
DrugBank: Poa annua pollen (DB10353)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Annual trans-vaginal ultrasound (TVU) for 4 years and CA-125 testing for 6 years with a cutoff at 35 U/mL
Study: 19083452
Drug: 1.5-g dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5-g dose of strong-gelling alginate
Study: 12941422
Drug: Monoclonal antibodies
Normalized name: Monoclonal antibodies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monoclonal antibodies used to deplete lymphocytes or block T-cell function
Study: 12941422
Drug: Conventional immunosuppressive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional immunosuppressive agents
Study: 7595729
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PC) with cyclophosphamide 600 mg/m2, epidoxorubicin 60 mg/m2, and fluorouracil 600 mg/m2 (CEF)
Study: 7595729
Drug: Perioperative chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative chemotherapy (PC)
Study: 2151889
Drug: Enoximone (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enoximone (0.5 mg/kg) + epinephrine (0.1 micrograms/kg/min)
Study: 28370357
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow-derived MSCs infused weekly for 4 weeks (1.0 to 10 × 10^5 cells/kg)
Study: 26215351
Drug: Cuddle therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cuddle therapy
Study: 23692975
Drug: Listerine® oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Listerine® oral rinse twice daily
Study: 23692975
Drug: Sodium bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium bicarbonate oral rinse 2/24